Sucampo Announces Third Quarter 2015 Earnings Call
October 21 2015 - 6:30AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global
biopharmaceutical company, today announced that it will host its
third quarter 2015 financial results teleconference and webcast at
8:30 a.m. Eastern on Wednesday, November 4, 2015. The press release
announcing the financial results and operating highlights is
expected to be released before the opening of capital markets that
day.
Individuals interested in accessing the live audio webcast of
the teleconference may do so at
http://www.sucampo.com/investors/events-presentations/ and should
log on 10 to 15 minutes before the teleconference begins to
download any software required. Presentation slides will be
available via the webcast link. A replay of the webcast will also
be available on Sucampo's website for several days after the live
event. Alternatively, individuals may dial 877-415-3180 (domestic)
or 857-244-7323 (international) and use passcode 25105024. A replay
of the teleconference will be available by dialing 888-286-8010
(domestic) or 617-801-6888 (international), passcode 68410149,
approximately two hours after the teleconference concludes. The
archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., is a global biopharmaceutical
company that is built on the ongoing pursuit of scientific
innovation to improve the lives of patients. Sucampo has a marketed
product – AMITIZA – and a pipeline including lifecycle management
and clinical development programs. Sucampo is headquartered in
Rockville, Maryland, and has operations in Japan, Switzerland and
the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter LinkedIn
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements include statements
regarding Sucampo's expectations for financial performance for the
full year 2015, as well as product development, [market] potential,
its strategy of pursing business development transactions and other
statements that are not historical facts. The following factors,
among others, could cause actual results to differ from those set
forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; the
ability of Sucampo to continue to develop the market for AMITIZA;
the ability of Sucampo to develop, commercialize or license
existing pipeline products or compounds or license or acquire
non-prostone products or drug candidates; Sucampo's ability to
accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for
innovative products; the risk of new and changing regulation and
health policies in the U.S. and internationally; the effects of
competitive products on Sucampo's products; and the exposure to
litigation and/or regulatory actions.
The forward-looking statements included in this press release
represent Sucampo's views as of the date of this press release. No
forward-looking statement can be guaranteed and actual results may
differ materially from those anticipated. Sucampo undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise. Forward-looking statements in this presentation should
be evaluated together with the many uncertainties that affect
Sucampo's business, particularly those mentioned in the risk
factors and cautionary statements in Sucampo's most recent Form
10-K as filed with the Securities and Exchange Commission on March
9, 2015 as well as its filings with the Securities and Exchange
Commission on Forms 8-K and 10-Q since the filing of the Form 10-K,
all of which Sucampo incorporates by reference. Accordingly,
these forward-looking statements should not be relied upon as
representing Sucampo's views as of any date subsequent to the date
of this press release.
CONTACT: Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President,
Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Jul 2023 to Jul 2024